Last reviewed · How we verify
NCT05269615
Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II
Phase 4 trial testing Valsartan 80 mg in Exercise Physiology in 80 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 80 |
| Start date | 20 March 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Valsartan 80 mg — full drug profile →
- Placebo
Conditions studied
- Exercise Physiology — all drugs for Exercise Physiology →
Sponsor
The University of Hong Kong
Who can join
20 and older, any sex, with Exercise Physiology. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The major aims are to determine the effect of acute (single dose) blockade of ANGII receptor 1 (AT1) on the EPO response to a single session of endurance exercise, as well as determine the effect of chronic (8-week) blockade of AT1 on ET-induced adaptations in total circulating red blood volume and hemoglobin.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Blockade of Angiotensin II Receptor Type 1 Abolishes the Erythropoietin Response to Exercise.
Guo M, Montero D. · · 2025 · cited 2× · PMID 40690272 · DOI 10.1093/function/zqaf032
Verify or expand the search:
- PubMed search for NCT05269615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Valsartan 80 mg
Trials testing the same drug.
- NCT05638880 — Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease · Phase 2 · completed
- NCT05881720 — Sacubitril/Valsartan Versus Valsartan in Heart Failure · Phase 4 · completed
- NCT03432468 — Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women · NA · unknown
- NCT03180593 — Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH · Phase 4 · completed
Other recruiting trials for Exercise Physiology
Currently open trials in the same condition.
- NCT07449663 — SPORT-SPECIFIC HIIT IN ELITE KICKBOXERS · NA · active not recruiting
- NCT07393841 — Molecular Indicators of Systematic Fitness · recruiting
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05269615 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 9 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05269615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing